Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancerDaniel G. Stover, Nancy U. Lin, Qiong Xu et al.|npj Breast Cancer|2018Cited by 150
JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell StatesLaura E. Stevens, Kornélia Polyák, Guillermo Peluffo et al.|Cancer Research|2022Cited by 101
The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II–III and metastatic breast cancersKaren S. Anderson, Beth Overmoyer|Breast Cancer Research and Treatment|2022Cited by 23